This is an open, blank controlled clinical trial to evaluate the efficacy and safety ofSA58 nasal spray in the prevention COVID-19 infection among health care workers at highrisk of SARS-CoV-2 infection.
This is an open, blank controlled clinical trial to evaluate the efficacy and safety of
SA58 nasal spray in the prevention COVID-19 infection among health care workers at high
risk of SARS-CoV-2 infection.The investigational drug was manufactured by Sinovac Life
Sciences Co. , Ltd.A total of 7000 medical personnel will be involved in this study: 3500
will use SA58 Nasal Spray in the drug group, and 3500 not use SA58 Nasal Spray in the
blank control group. The medication is self-administered intranasally 1~2 times per day
with an interval of 6 hours for about 30 days.
Drug: SA58 Nasal Spray
SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of
neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20
sprays per bottle.
Inclusion Criteria:
- Medical staff working in the designated COVID-19 hospitals and Fangcang shelter
hospitals (alternate care sites) of COVID-19 cases in Hohhot;
- Subjects were 18 years of age and older and in good health;
- Subjects volunteered to use COVID-19 neutralizing antibody nasal spray.
Exclusion Criteria:
- Previous history of severe allergies or sensitivity to inhaled allergens;
- Women were pregnant or breastfeeding;
- Subjects were unable to cooperate with nasal spray inhalation;
- Other conditions for which medication was not appropriate.
Inner Mongolia Fourth Hospital
Hohhot, The Inner Mongolia Autonomous Region, China
Shuo Zhang, Principal Investigator
Inner Mongolia Fourth Hospital